Name: (2S)-p-SCN-Bn-NOTA
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

1H-1,4,7-Triazonine-1,4,7-triacetic acid, hexahydro-2-[(4-isothiocyanatophenyl)methyl]-, (2S)-; (S)-2,2',2''-(2-(4-isothiocyanatobenzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid; (2S)-Hexahydro-2-[(4-isothiocyanatophenyl)methyl]-1H-1,4,7-triazonine-1,4,7-triacetic acid; BNOTA; p-SCN-Bn-NOTA; S-2-(4-Isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid; (2S)-2-(4-Isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid; (S)-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid

IUPAC Name

2-[(5S)-4,7-bis(carboxymethyl)-5-[(4-isothiocyanatophenyl)methyl]-1,4,7-triazonan-1-yl]acetic acid

Canonical SMILES

C1CN(CC(N(CCN1CC(=O)O)CC(=O)O)CC2=CC=C(C=C2)N=C=S)CC(=O)O

InChI

InChI=1S/C20H26N4O6S/c25-18(26)11-22-5-6-23(12-19(27)28)10-17(24(8-7-22)13-20(29)30)9-15-1-3-16(4-2-15)21-14-31/h1-4,17H,5-13H2,(H,25,26)(H,27,28)(H,29,30)/t17-/m0/s1

InChIKey

ABEIJMWLNYUWMD-KRWDZBQOSA-N

Density

1.37±0.1 g/cm3

Boiling Point

716.5±60.0°C at 760 mmHg

(2S)-p-SCN-Bn-NOTA, a versatile chelating agent, plays a pivotal role in radiolabeling biomolecules, particularly in the realm of medical imaging. Here are four key applications presented with a high degree of perplexity and burstiness:

Radiopharmaceutical Development: At the forefront of medical imaging, (2S)-p-SCN-Bn-NOTA is indispensable for synthesizing radiopharmaceuticals utilized in positron emission tomography (PET) and single-photon emission computed tomography (SPECT). By conjugating radioisotopes to biomolecules, it facilitates real-time visualization of specific biological processes within living organisms. This capability is paramount for early disease detection, monitoring treatment efficacy, and advancing biomedical research endeavors.

Cancer Imaging: In the field of oncology, (2S)-p-SCN-Bn-NOTA is harnessed to radiolabel antibodies or peptides that target tumor-specific antigens. This targeted imaging approach enables precise visualization of tumors and metastases, aiding in accurate cancer staging and assessment of disease progression. Oncologists can tailor individualized treatment strategies based on the unique characteristics of each patient's cancer, ultimately enhancing therapeutic outcomes.

Neurological Disorder Research: Exploring the intricacies of neurological disorders, such as Alzheimer's and Parkinson's diseases, (2S)-p-SCN-Bn-NOTA-labeled compounds offer valuable insights. By selectively binding to specific proteins or receptors in the brain, these compounds yield detailed images of pathological alterations, shedding light on disease mechanisms. This imaging modality empowers researchers to evaluate novel treatment approaches and deepen their understanding of complex neurological conditions.

Cardiac Imaging: In the realm of cardiovascular health, (2S)-p-SCN-Bn-NOTA is a critical component in the development of radiolabeled tracers for cardiac imaging applications. These tracers aid in assessing myocardial perfusion and detecting ischemic heart disease by precisely localizing radiotracers within the heart. This technology plays a crucial role in evaluating cardiac function, pinpointing areas of compromised blood flow, and informing accurate diagnoses and treatment strategies for various cardiac conditions.